phase readout

NCT06445400: A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

ACTIVE_NOT_RECRUITINGupdated 1mo ago

community read0 votes

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.. Phase: PHASE2. Conditions: HER2-positive Breast Cancer

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 1h ago

Found something off?